Literature DB >> 34520542

Theoretical basis for stabilizing messenger RNA through secondary structure design.

Hannah K Wayment-Steele1,2, Do Soon Kim2,3,4, Christian A Choe2,5, John J Nicol2, Roger Wellington-Oguri2, Andrew M Watkins2,4, R Andres Parra Sperberg5, Po-Ssu Huang5, Eterna Participants2, Rhiju Das2,4,6.   

Abstract

RNA hydrolysis presents problems in manufacturing, long-term storage, world-wide delivery and in vivo stability of messenger RNA (mRNA)-based vaccines and therapeutics. A largely unexplored strategy to reduce mRNA hydrolysis is to redesign RNAs to form double-stranded regions, which are protected from in-line cleavage and enzymatic degradation, while coding for the same proteins. The amount of stabilization that this strategy can deliver and the most effective algorithmic approach to achieve stabilization remain poorly understood. Here, we present simple calculations for estimating RNA stability against hydrolysis, and a model that links the average unpaired probability of an mRNA, or AUP, to its overall hydrolysis rate. To characterize the stabilization achievable through structure design, we compare AUP optimization by conventional mRNA design methods to results from more computationally sophisticated algorithms and crowdsourcing through the OpenVaccine challenge on the Eterna platform. We find that rational design on Eterna and the more sophisticated algorithms lead to constructs with low AUP, which we term 'superfolder' mRNAs. These designs exhibit a wide diversity of sequence and structure features that may be desirable for translation, biophysical size, and immunogenicity. Furthermore, their folding is robust to temperature, computer modeling method, choice of flanking untranslated regions, and changes in target protein sequence, as illustrated by rapid redesign of superfolder mRNAs for B.1.351, P.1 and B.1.1.7 variants of the prefusion-stabilized SARS-CoV-2 spike protein. Increases in in vitro mRNA half-life by at least two-fold appear immediately achievable.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34520542      PMCID: PMC8499941          DOI: 10.1093/nar/gkab764

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  14 in total

1.  Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach.

Authors:  Han Han Ly; Simon Daniel; Shekinah K V Soriano; Zoltán Kis; Anna K Blakney
Journal:  Mol Pharm       Date:  2022-05-23       Impact factor: 5.364

Review 2.  A Biopharmaceutical Perspective on Higher-Order Structure and Thermal Stability of mRNA Vaccines.

Authors:  Marek Kloczewiak; Jessica M Banks; Lin Jin; Mark L Brader
Journal:  Mol Pharm       Date:  2022-06-17       Impact factor: 5.364

3.  Nearest neighbor rules for RNA helix folding thermodynamics: improved end effects.

Authors:  Jeffrey Zuber; Susan J Schroeder; Hongying Sun; Douglas H Turner; David H Mathews
Journal:  Nucleic Acids Res       Date:  2022-05-20       Impact factor: 19.160

4.  Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics.

Authors:  Kathrin Leppek; Gun Woo Byeon; Wipapat Kladwang; Hannah K Wayment-Steele; Craig H Kerr; Adele F Xu; Do Soon Kim; Ved V Topkar; Christian Choe; Daphna Rothschild; Gerald C Tiu; Roger Wellington-Oguri; Kotaro Fujii; Eesha Sharma; Andrew M Watkins; John J Nicol; Jonathan Romano; Bojan Tunguz; Fernando Diaz; Hui Cai; Pengbo Guo; Jiewei Wu; Fanyu Meng; Shuai Shi; Eterna Participants; Philip R Dormitzer; Alicia Solórzano; Maria Barna; Rhiju Das
Journal:  Nat Commun       Date:  2022-03-22       Impact factor: 17.694

Review 5.  Principles for designing an optimal mRNA lipid nanoparticle vaccine.

Authors:  Edo Kon; Uri Elia; Dan Peer
Journal:  Curr Opin Biotechnol       Date:  2021-10-26       Impact factor: 9.740

Review 6.  Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain.

Authors:  Zoltán Kis
Journal:  Pharmaceutics       Date:  2022-02-17       Impact factor: 6.321

Review 7.  mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.

Authors:  Ting Le; Chao Sun; Jitao Chang; Guijie Zhang; Xin Yin
Journal:  Viruses       Date:  2022-02-15       Impact factor: 5.048

Review 8.  A brief review of mRNA therapeutics and delivery for bone tissue engineering.

Authors:  Arun Kumar Rajendran; Sivashanmugam Amirthalingam; Nathaniel S Hwang
Journal:  RSC Adv       Date:  2022-03-22       Impact factor: 3.361

Review 9.  mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles.

Authors:  Andreas Ouranidis; Theofanis Vavilis; Evdokia Mandala; Christina Davidopoulou; Eleni Stamoula; Catherine K Markopoulou; Anna Karagianni; Kyriakos Kachrimanis
Journal:  Biomedicines       Date:  2021-12-27

Review 10.  Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency.

Authors:  Sun Chang Kim; Simranjeet Singh Sekhon; Woo-Ri Shin; Gna Ahn; Byung-Kwan Cho; Ji-Young Ahn; Yang-Hoon Kim
Journal:  Mol Cell Toxicol       Date:  2021-09-20       Impact factor: 1.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.